PGNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Progyny Inc (PGNY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown positive financial growth in the latest quarter and has a strong position in women's health and family building solutions, the stock faces significant headwinds, including insider selling, cautious analyst sentiment, and a lack of strong trading signals. The technical indicators are neutral, and options data does not indicate strong bullish sentiment. It is better to wait for more clarity on membership trends and financial results before making a decision.
The MACD is positive but contracting, RSI is neutral at 49.256, and moving averages are converging, indicating no clear trend. Key support is at 16.467, and resistance is at 18.667. The stock is trading near its pivot point of 17.567, suggesting limited immediate upside.
Positive financial growth in Q4 2025, with revenue up 6.69% YoY, net income up 18.54% YoY, and EPS up 27.27% YoY.
Recognition as a global leader in women's health and family building solutions, with accolades like TIME100 and CNBC Disruptor 50.
Insider selling has increased by 601.40% over the last month.
Analysts have lowered price targets, citing concerns about membership trends and broader layoffs affecting growth.
Hedge funds are neutral, and there are no significant trading trends.
Lack of strong trading signals from AI Stock Picker or SwingMax.
In Q4 2025, Progyny reported revenue of $318.4M (up 6.69% YoY), net income of $12.49M (up 18.54% YoY), EPS of $0.14 (up 27.27% YoY), and gross margin of 24.15% (up 13.59% YoY). These figures indicate stable growth despite challenges.
Analysts have lowered price targets recently, with Barclays reducing to $23, Canaccord to $19, BTIG to $30, Truist to $28, and KeyBanc to $28. Ratings range from Hold to Buy, with cautious optimism about long-term growth but concerns about near-term membership trends and broader economic factors.
